TRANSITION OF IV TREPROSTINIL TO ORAL SELEXIPAG IN PULMONARY ARTERIAL HYPERTENSION

被引：0
|
作者：
Mahoney, Roshan
Sweidan, Alexander
Yaghmour, Bassam
机构：
来源：
CHEST | 2021年 / 160卷 / 04期
关键词：
D O I：
10.1016/j.chest.2021.07.1963
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：2229A / 2229A
页数：1
相关论文
共 50 条
  • [21] Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension
    Radosevich, John J.
    DeChristopher, Audra
    Irandost, Maykel
    Fann, Jade
    Feldman, Jeremy
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2020, 77 (15) : 1208 - 1212
  • [22] Oral treprostinil in the treatment of pulmonary arterial hypertension
    Feldman, Jeremy
    Habib, Naomi
    Radosevich, John
    Dutt, Mohan
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (15) : 1661 - 1667
  • [23] Tolerability And Safety Of Transition From Inhaled Treprostinil To Oral Selexipag In Pulmonary Arterial Hypertension: Results From The Transit-1 Study
    Frost, A. E.
    Janmohamed, M.
    Fritz, J.
    McConnell, J. W.
    Poch, D.
    Fortin, T.
    Miller, C.
    Chin, K.
    Fisher, M. R.
    Eggert, M.
    McEvoy, C.
    Benza, R. L.
    Farber, H. W.
    Kim, N. H.
    Hartline, B.
    Pfister, T.
    Shiraga, Y.
    McLaughlin, V.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [24] Functional Outcomes Of Selexipag Versus Inhaled Treprostinil For The Treatment Of Pulmonary Arterial Hypertension
    Pallazola, V. A.
    Visovatti, S.
    McLaughlin, V.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [25] Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry
    Lachant, D.
    Minkin, R.
    Swisher, J.
    Mogri, M.
    Zolty, R.
    Hwang, S.
    Seaman, S.
    Broderick, M.
    Sahay, S.
    [J]. PULMONARY PHARMACOLOGY & THERAPEUTICS, 2023, 82
  • [26] Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension
    Ivy, D. Dunbar
    Feinstein, Jeffrey A.
    Yung, Delphine
    Mullen, Mary P.
    Kirkpatrick, Edward C.
    Hirsch, Russel
    Austin, Eric D.
    Fineman, Jeffrey
    Truong, Uyen
    Solum, Derek
    Deng, C. Q.
    Hopper, Rachel K.
    [J]. PULMONARY CIRCULATION, 2019, 9 (03)
  • [27] Beneficial Effects of Treprostinil Palmitil in a Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension; a Comparison with Inhaled and Intravenous Treprostinil and Oral Selexipag
    Corboz, M. R.
    Plaunt, A. J.
    Malinin, V.
    Li, Z.
    Gauani, H.
    Chun, D.
    Cipolla, D.
    Perkins, W.
    Chapman, R. W.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [28] Safety And Tolerability Of Outpatient Transition Of Parenteral And Inhaled Treprostinil To Oral Treprostinil In Patients With Pulmonary Arterial Hypertension
    Khan, A. A.
    Ackerbauer, K.
    Tandon, R.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [29] Successful Transition From Oral Selexipag to Treprostinil
    Pham, A.
    Techasatian, W.
    Devendra, G.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [30] Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: A controlled trial
    Rubenfire, Melvyn
    McLaughlin, Vallerle V.
    Allen, Roblee P.
    Elliott, Greg
    Park, Myung H.
    Wade, Michael
    Schilz, Robert
    [J]. CHEST, 2007, 132 (03) : 757 - 763
12345